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Skin Retinoid Concentrations Are Modulated by
CYP26AI Expression Restricted to Basal Keratinocytes
in Normal Human Skin and Differentiated 3D
Skin Models
Ruth Heise1, Jo¨rg Mey2, Mark M. Neis1, Yvonne Marquardt1, Sylvia Joussen1, Hagen Ott1, Tonio Wiederholt1,
Peter Kurschat3, Mosaad Megahed1, David R. Bickers4, Hans F. Merk1 and Jens M. Baron1
Cellular levels of all-trans retinoic acid (RA) are meticulously regulated utilizing an array of systems to balance
uptake, biosynthesis, catabolism, and efflux transport. Metabolic transformation of all-trans RA to
4-hydroxylated RA appears to be primarily catalyzed by the cytochrome P450 (CYP) 26AI. Analysis of monolayer
cultures of normal human epidermal keratinocytes (NHEKs) and dermal fibroblasts by quantitative real-time
PCR and reverse transcription-PCR revealed no basal levels of CYP26AI mRNA expression, whereas specific
transcripts were detectable following addition of 106 M all-trans RA. Immunofluorescence and Western blot
analysis showed a weak expression of CYP26AI in NHEK, which was increased by stimulation with all-trans RA.
Using a newly developed peptide antibody, we further examined the localization of CYP26AI expression in
normal skin and three-dimensional (3D) skin models. In contrast to cell culture monolayers where CYP26AI was
only weakly detectable, strong constitutive expression of CYP26AI in vivo and in organotypic culture was found
to be restricted to basal epidermal keratinocytes, as well as eccrine sweat glands and sebaceous glands. These
studies verify the capacity of human skin to metabolize RA, although substantial differences exist in CYP
expression between normal skin and 3D skin models compared to monolayer cultures. Complex metabolic
processes that maintain retinoid homeostasis may therefore be better studied in model systems more closely
resembling in vivo skin. In light of our prior studies documenting the functional activity of RA metabolites,
expression of CYP26 in the sebaceous gland epithelium supports the suggestion that altered RA metabolism
may be involved in the pathogenesis of acne.
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INTRODUCTION
Retinoids have a wide range of biological effects. They are
potent regulators of cell proliferation, cell differentiation, and
morphogenesis (Gudas et al., 1994). Owing to these actions,
retinoids such as retinoic acid (RA) are important therapeutic
agents for the treatment of numerous dermatological dis-
orders such as psoriasis and acne (Roos et al., 1998;
Zouboulis, 2001a, b). The effects of retinoids on gene
expression are mediated by a family of ligand-dependent
nuclear RA receptors (RARs a, b, and g) and retinoid X
receptors (RXRs a, b, and g). RARs and RXRs commonly
participate together, in the form of heterodimers, to regulate
transcription (Mangelsdorf et al., 1995; Chambon, 1996;
Chawla et al., 2001).
Cellular levels of all-trans RA are stringently regulated
through a balance of uptake, biosynthesis, catabolism, and
efflux transport (McSorley and Daly, 2000; Dreuw et al.,
2005). In human skin, the primary metabolite of all-trans RA
is 4-hydroxy all-trans RA, which is further metabolized to
4-oxo all-trans RA. Recently, we showed that the RA metabolite
4-oxo-RA exerts pharmacological effects in human skin cells
(Baron et al., 2005). However, the metabolic pathways for RA
transformation are only partially understood and the specific
cytochrome P450 (CYP) enzyme responsible for the conver-
sion of RA to 4-oxo-RA in human skin has not been defined.
Smith et al. (2003) recently identified CYP2S1 (Rylander
et al., 2001) in human skin cells and showed its capacity to
metabolize all-trans RA. They were able to show an up to
2-fold change in CYP2S1 mRNA expression after induction of
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human skin with topically applied all-trans RA. Duell et al.
(1992) described a 4.5-fold increase in metabolism of all-
trans RA to 4-oxo all-trans RA in skin treated with all-trans
RA. These data may suggest that CYP2S1 is not the only CYP
enzyme responsible for RA metabolism in human skin.
Roos et al. (1998) mentioned data by Wyss that there are
no differences in the oxidizing activity of 4-OH-RA in
cultured human keratinocytes and fibroblasts compared to
tissue culture medium. This would suggest that 4-OH-RA is
oxidized spontaneously to 4-oxo RA. In contrast, incubation
of all-trans RA with heterologously expressed CYP2S1 (Smith
et al., 2003) revealed the production of 4-hydroxy-RA and
5,6-epoxy-RA but not of 4-oxo RA. This would further add to
the suggestion that expression of another CYP oxidase may be
responsible for the oxidization of 4-OH-RA in skin.
Hydroxylation of RA to the less active and more readily
excreteable polar metabolite 4-OH RA is also mediated by
the highly specific CYP enzyme CYP26, which is expressed in
many tissues, including kidney, lung, and liver and in a
number of cell lines (Ray et al., 1997; White et al., 1997). Its
expression is induced in vitro and in vivo by its natural
substrate all-trans RA to modulate the biological activity of
all-trans RA (Randolph and Simon, 1997; Ray et al., 1997;
Abu-Abed et al., 1998; Loudig et al., 2000).
To evaluate the role of this enzyme in retinoid homeostasis
of the skin, we examined the expression and inducibility of
CYP26AI in normal human epidermal keratinocytes (NHEKs)
and dermal fibroblasts as well as human skin specimens and
three-dimensional (3D) skin models.
RESULTS
Effect of all-trans RA on CYP26 mRNA and protein expression in
NHEK and human dermal fibroblasts in monolayer cultures
Proliferating NHEK and primary human dermal fibroblasts
isolated from foreskin were treated with 106 M all-trans RA
and 4-oxo-all-trans RA for 24 hours (Figure 1). Expression of
CYP26AI was assessed by semiquantitative reverse transcrip-
tion-PCR (RT-PCR) and real-time PCR (TaqMan). As shown in
Figure 1a and c, CYP26A1 mRNA expression could not be
detected in untreated and DMSO-treated NHEK and fibro-
blasts. After incubation of cells with all-trans RA (Figure 1a)
or 4-oxo-all-trans RA (Figure 1b) for 24 hours, expression of
this CYP enzyme was induced. Additionally, we confirmed
these RT-PCR data using real-time PCR (data not shown).
Incubation of NHEK and fibroblasts with all-trans RA and its
4-oxo metabolite for 24 hours tended to result in a weak
upregulation of CYP26AI expression. A quantitative calcula-
tion of this data was not possible, because of insufficient
basal expression of CYP26AI in control cells.
For Western blot analysis (Figure 2), NHEKs were treated
for the indicated time points with 106 M all-trans RA.
CYP26AI protein levels were analyzed using a newly
developed antibody specific for this isozyme. In NHEK, weak
constitutive expression was seen after 12 and 24 hours in the
DMSO-treated controls (Figure 2a). Addition of all-trans RA
for 12 hours resulted in 2-fold induction of CYP26AI
expression and after 24 h the induction increased to 3-fold.
After 48 and 72 hours of incubation, CYP26AI was strongly
expressed in the DMSO-treated probes and addition of all-
trans RA did not result in further increase in CYP26AI
expression. Using ethanol as solvent, only weak expression of
CYP26 was found at all time points analyzed (Figure 1b).
According to the data using DMSO as solvent, incubation of
NHEK with all-trans RA resulted in a significant upregulation
of CYP26 protein expression (Figure 1b). Dermal fibroblast
revealed a constitutive expression of CYP26, but incubation
of cells with all-trans RA showed no significant upregulation
(data not shown).
For immunofluorescence examination (Figure 3) of CY-
P26AI expression in NHEK monolayers, cells were seeded
into chamber slides and 106 M all-trans RA was added.
DMSO alone served as control. Twenty-four and 48 hours
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Figure 1. RT-PCR of CYP26AI expression in normal human epidermal keratinocytes and primary human dermal fibroblasts in response to all-trans RA
or 4-oxo-all-trans RA. For RT-PCR analysis, NHEK (a and b) and dermal fibroblasts (c) were stimulated with 106 M all-trans RA (a and c) or 4-oxo-all-trans
RA (b) dissolved in DMSO and untreated as well as DMSO-treated cells were used as control. Cells were harvested 24 hours after induction. RT-PCR was
performed using specific primers for CYP26AI (50 to 30: sense: AGG CAC TAA AGC AAT CTT CAA; antisense: CAT GGA AAT GGG TGA ATC TTG) and b-actin
(50 to 30: sense: CGG AAC CGC TCA TTG CC; antisense: CGG AAC CGC TCA TTG CC). PCR products of CYP26AI and b-actin as internal standard were
separated on agarose gels and stained with ethidium bromide.
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after treatment, the stimulatory effect of all-trans RA was
assessed with the primary peptide antibody against the N-
terminus of CYP26AI. In control cells, weak constitutive
expression of CYP26AI was seen. The RA-treated cells
showed increased cytoplasmic staining of CYP26A1.
Detection of CYP26 protein in normal skin, psoriasis, and 3D
skin models using immunofluorescence
Immunofluorescence staining of normal human skin clearly
demonstrated expression of CYP26AI in the cytoplasm of
basal keratinocytes (Figure 4a; CYP26AI expression indicated
by arrow). A similar expression pattern was seen in a
specimen obtained from a psoriatic plaque (Figure 4b). Using
the newly developed peptide antibody, we further examined
the localization of CYP26AI expression in 3D skin models
cultured for 7 (Figure 4c) and 21 days (Figure 4d). The
21-day-old 3D model system (Figure 4d) revealed similar
histological features and a similar expression pattern of
CYP26AI compared to normal human skin (Figure 4a).
Incubation of 3D skin models with liquor carbonis detergens
0.2625% for 24 hours did not alter the expression of CYP26AI
(Figure 4e and f).
Immunohistochemical detection of CYP26 protein expression in
normal human skin
Immunohistochemical analysis using a newly developed
antibody specific for CYP26AI revealed strong constitutive
expression of the CYP26AI protein, especially in the
cytoplasm of keratinocytes of the epidermal basal layer
(Figure 5a and d). No significant staining of collagen fibers,
nerves, smooth muscles, small and medium sized venules,
arterioles, and fat cells could be detected (Figure 5a).
Epithelial cells of the eccrine sweat gland (Figure 5c) and
the sebaceous gland (Figure 5b) were strongly positive in a
pattern similar to that seen in basal keratinocytes.
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Figure 2. Western blot analysis of CYP26AI expression in normal human epidermal keratinocytes in response to all-trans RA using different solvents. For
Western blot analysis, NHEK were stimulated with 106 M all-trans RA dissolved in DMSO (a) or ethanol (b) and, DMSO- or ethanol-treated cells were used
as control. Cells were harvested at the indicated time points and total cell lysates were prepared and separated by SDS-PAGE. Western blots were developed
with a generated anti-peptide antibody against the N-terminus of CYP26AI. Blots were stripped and reprobed with a primary monoclonal anti-human b-actin
antibody. CYP26AI relative immunoreactivity related to b-actin immunoreativity was defined by performing a densidometric analysis.
Control (DMSO) All-trans RA (10–6 M)
24 hours
48 hours
Figure 3. Immunofluorescence examination of CYP26AI expression in
keratinocyte monolayers. Keratinocytes were cultivated in chamber slides
and stimulated with 106 M all-trans RA for 24 and 48 hours. DMSO-treated
cells were used as control. Intracellular staining of CYP26AI was performed
using a generated peptide antibody specific for the detection of the
N-terminus of CYP26AI.
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DISCUSSION
Retinoids, including all-trans RA, play important roles in
regulating gene expression through interactions with nuclear
receptors, during embryonic development (Abu-Abed et al.,
2002; Niederreither et al., 2002) and in the homeostasis of
adult epithelial tissues (Chambon, 1995). There is good
evidence to indicate that 4-hydroxylation of RA inside the
target cell limits its biological activity and initiates a
degradative process for RA leading to its eventual elimina-
tion, although 4-oxo-RA metabolites do show some effects in
human skin (Baron et al., 2005).
In 1997, the first mammalian RA-inducible retinoid acid-
metabolizing CYP (CYP26AI) was cloned (Ray et al., 1997;
White et al., 1997). White et al. (1997) were able to prove
that CYP26AI generates several hydroxylated forms of RA,
including 4-OH-RA, 4-oxo-RA, and 18-OH RA, in COS-1
cells transfected with a human CYP26AI-expressing vector.
They also showed that MCF10A cells in which no inducible
expression of CYP26AI was detectable did not generate 4-oxo
or 4-OH RA in either control or RA-treated cells. In contrast,
MCF7 cells with highly inducible CYP26AI expression
produce these metabolites in response to treatment with
all-trans RA (White et al., 1997).
As it was clear that human skin keratinocytes can
metabolize RA, it was tempting to speculate that this was
owing to CYP26AI activity. Using RT-PCR and probing blots
of PCR products, Popa et al. (1999) found weak CYP26AI
mRNA expression in the epidermis and keratinocytes and
found no evidence for the inducibility of CYP26AI mRNA.
They concluded that CYP26AI is unlikely to contribute to RA
metabolism in keratinocytes. Using RT- and real-time PCR
(data not shown), we could not detect basal expression of
CYP26AI mRNA in monolayer cultures of NHEK or dermal
fibroblasts (Figure 1). These results are in accordance with the
findings of Popa et al. (1999), who were not able to detect
CYP26 mRNA expression on an ethidium bromide-stained
gel. In contrast to their data, incubation of NHEK with all-
trans RA led to weak induction of CYP26AI mRNA expression
(Figure 1a). This difference may be owing to the late point of
analysis (48 hours) in the studies of Popa et al. (1999) – in our
studies, NHEKs were yielded and analyzed after 24 hours – or
to donor variability.
The main differences between our studies and those of
Popa et al. (1999) are that they did not look for the protein
expression of CYP26AI in human skin tissues or organotypic
3D culture systems. Therefore, the strong expression of this
CYP, whose expression is mainly restricted to the basal layer
of the epidermis (Figures 4a and 5a/d), was missed. This focal
staining may explain why mRNA expression could not be
detected by RT- or real-time PCR analysis of whole-skin
samples (Figure 1a). Differences between mRNA and protein
expression in keratinocyte monolayers may be owing to post-
transcriptional acetylation and protein stabilization, which
would prevent protein ubiquitination and degradation in the
proteasome. It has been reported before that ethanol
regulates the expression of CYP2E1 by post-translational
stabilization making it resistant to the proteolytic digestion
(Ramana and Kohli, 1998).
In 2003, Smith et al. identified CYP2S1 in skin samples of
healthy volunteers and patients with psoriasis by real-time
PCR. Interestingly, they revealed that the CYP2S1 expressed
in E. coli was unable to metabolize all-trans RA to 4-oxo-RA,
and that the treatment of skin samples with all-trans RA
resulted in 2-fold upregulation of CYP2S1 expression. As
Duell et al. (1992) had shown that topical application of
0.1% RA cream led to a 4.5-fold upregulation of 4-OH RA
formation and a 2.6 increase in 4-oxo-RA formation in
human skin samples, it seems reasonable that CYP2S1 is one
of multiple enzymes responsible for RA metabolism in human
skin. In contrast to CYP2S1 (Smith et al., 2003), expression of
CYP26A1 was not increased in a skin specimen from a
patient with psoriasis (Figure 4b), indicating a different
mechanism of gene regulation. Smith et al. (2003) also
described induction of CYP2S1 in skin samples treated with
coal tar. Incubation of 3D skin models with a form of coal tar
known as liquor carbonis detergens had no effect on
CYP26AI expression (Figure 4e and f). This could be
explained by differences in the regulation of the expression
a c e
b d f
Figure 4. Immunofluorescence examination of human skin specimens and 3D skin models using peptide antibody specific for the N-terminus of CYP26AI.
(a) Staining of normal skin, (b) skin sample taken from a patient with psoriasis, (c) 3D skin model day 7, (d) 3D skin model day 21, (e) 3D skin model day 14,
and (f) 3D skin model day 14 incubated for 24 hours with 0.2625% liquor carbonis detergens. ) Indicates expression of CYP26AI in keratinocytes of the
stratum basale.
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of both RA-metabolizing enzymes, as expression of CYP2S1
is influenced by the aryl hydrocarbon receptor pathway
(Rivera et al., 2002). In contrast, induction of RA 4-hydroxy-
lase by all-trans RA in keratinocytes seems to be dependent
on nuclear RA receptor-mediated gene transcription (Marikar
et al., 1998).
Interestingly, 3D skin equivalents in which differentiation
closely resembles that of human skin showed a similar
expression pattern of CYP26AI located to the epidermal basal
layer (Figure 4d). In contrast, untreated monolayer cultures
have barely detectable protein (Figure 3). These differences
between keratinocytes in vivo and in vitro may be explained
by crosstalk among retinoid and other signalling pathways,
most notably transcription factor AP-1, as well as differences
in the expression of RA and retinoic X receptors (Fisher and
Voorhees, 1996). Other signals present in vivo that are absent
in monolayer culture are those derived from the connective
tissue matrix of the dermis, which are known to influence the
growth and differentiation of keratinocytes. These include
soluble mediators such as growth factors (e.g. keratinocytes
growth factor or insulin-like growth factor) as well as physical
interactions of basal keratinocytes with structural proteins of
the basement membrane (Fisher and Voorhees, 1996).
Therefore, complex metabolic processes such as retinoid
metabolism should be studied in model systems more closely
resembling in vivo skin such as the 3D systems employed
here.
In addition to their effect on growth and differentiation,
retinoids exert anti-inflammatory actions and suppress sebum
production in sebaceous glands (Gollnick, 2003). In an
immortalized human sebaceous gland cell line, the addition
of retinoids to culture medium significantly reduced sebocyte
proliferation (Tsukada et al., 2002). Our novel finding that
cells of the sebaceous gland in healthy human skin reveal a
specific and significant expression of CYP26AI (Figure 5b)
may enhance current understanding of the pathogenesis and
treatment of diseases of the sebaceous follicle such as acne.
Although untreated and RA-stimulated SZ95 sebocytes reveal
no expression of CYP26 mRNA (Tsukada et al., 2002), the
expression of CYP26AI in the epithelium of sebaceous glands
(Figure 5b) may determine how the sebaceous follicle
responds to acnegenic stimuli.
In summary, these findings indicate that CYP26AI plays a
major role in the formation of 4-OH metabolites of RA in
human skin. Along with CYP2S1, it may be the predominant
enzyme in the skin especially being capable of forming
4-oxo-RA. The expression of CYP26AI in sebaceous gland
epithelium may provide new insights into the pathogenesis
and treatment of diseases of the sebaceous follicle. Future
studies should focus on the mechanisms responsible for the
selective expression of this CYP in basal layer keratinocytes.
MATERIALS AND METHODS
Normal human epidermal keratinocytes
NHEKs were obtained from neonatal foreskins by dispase (BD
Biosciences, Bedford, MA) separation of the epidermal sheet from
the dermis and subsequent trypsin (Cambrex, Walkersville, MD)
digestion of the epidermis. Trypsin was neutralized with Trypsin
Neutralisation Solution (Cambrex). Cells were fed with Keratinocyte
Growth Medium (KGM bullet kit C3111, Cambrex) three times a
week. For this study, proliferating keratinocytes in the first and
second passages were used.
Normal human fibroblasts were obtained from the same fore-
skins. After separation of the epidermal sheet from the dermis by
dispase (BD Biosciences), a single-cell suspension of fibroblasts was
generated by incubating the dermis in collagenase 1A (Sigma,
Taufkirchen, Germany). Fibroblasts were fed three times a week with
DMEM containing 4 g/l glucose and L-glutamine (Gibco/Invitrogen,
Paisley, UK) and supplemented with 10% fetal calf serum (FCS;
Biochrom, Berlin, Germany).
Human skin specimens
Skin sample of a patient with psoriasis was obtained in the
Department of Dermatology, RWTH Aachen. This study was
a
b c d
Normal skin
Sebaceous gland Eccrine sweat gland Epidermis
Figure 5. Immunohistochemistry of CYP26 expression in normal skin. (a) Overview, (b) staining of the sebaceous gland, (c) the eccrine sweat gland,
and (d) the epidermis. indicates an isotypic control, ) indicates expression of CYP26AI. Bar¼ 200 mm.
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approved by the ethical committee of the University Hospital,
RWTH, Aachen. The participant gave his written informed consent,
and the study was conducted according to the Declaration of
Helsinki Principles.
Skin equivalents
To construct the dermal equivalents of the 3D skin models, collagen
gels were prepared by mixing eight volumes of ice-cold bovine
collagen type I solution (Vitrogen, Cohesion, Palo Alto, CA) with one
volume of  10 concentrated Hank’s balanced salt solution (HBSS;
Gibco/Invitrogen). After neutralization with 1 M NaOH, one volume
of fibroblasts suspended in FCS was added. The final concentration
of fibroblasts in this gel solution was 1 105 cells/ml. Four milliliters
of this gel solution was poured into each polycarbonate membrane
insert (0.4 mm pore size, 25 mm diameter; Nunc). Then, inserts were
placed in six-well plates. Following complete polymerization, gels
were covered with DMEM containing 10% FCS, 100 U/ml penicillin,
and 100 mg/ml streptomycin and incubated in a humidified 5% CO2
atmosphere at 371C. After 2 days, keratinocytes were seeded at a
density of 2 106 cells/well onto the collagen gels. The skin
equivalents were cultured in a medium consisting of 50% KGM
and 50% DMEM supplemented with 5% FCS, 100 U/ml penicillin,
100 mg/ml streptomycin, and 50 mg/ml ascorbic acid. After 2–4 days
of submerged culture, skin equivalents were lifted to the air–liquid
interface and the calcium concentration in the medium was raised to
1.2 mM (Hoeller et al., 2001; Hinterhuber et al., 2002).
Retinoid treatment of the cells
Under dim red light, all-trans RA or 4-oxo-all-trans RA (kindly
provided by Dr Ulf Wiegand, F Hoffman La-Roche, Basel, Switzer-
land), freshly prepared as a stock in DMSO or ethanol (Merck,
Darmstadt, Germany), was added to cultured NEHKs or dermal
fibroblasts to a final concentration of 106 M. Treated cells were
incubated for the indicated timespans in a 5% CO2 humidified
atmosphere at 371C in the dark. Control cells were treated with an
equal amount of DMSO or ethanol.
RNA isolation
Total RNA from NHEK or human dermal fibroblasts was isolated
using the high-pure RNA isolation kit (Roche, Mannheim, Germany)
according to the manufacturer’s instructions, including efficient on-
column digestion of DNA with RNase-free DNase I. RNA
concentration of each sample was measured using the Nanodrop
system (NanoDrop Technologies, Rockland, Delaware) and equal
amounts of RNA were used for RT-PCR and quantitative real-time PCR.
RT-PCR
RT and PCR were performed with the GeneAmp RNA PCR kit
(Perkin-Elmer, Weiterstadt, Germany) according to the manufac-
turer’s instructions. Detection of specific transcripts for CYP26AI was
achieved by using primers designed to amplify at least one intron in
the gene to exclude contamination of cDNA with genomic DNA
(50 to 30: sense: AGG CAC TAA AGC AAT CTT CAA; antisense: CAT
GGA AAT GGG TGA ATC TTG). b-Actin was used as an internal
standard as described before (Baron et al., 2001). Amplification was
carried out with 35 cycles of 1 minute denaturation at 941C,
1 minute annealing at 531C, and 1 minute extension at 721C.
Amplification was terminated with an extension step of 10 minutes
duration at 721C after the last cycle. PCR products were separated
on 1.8% agarose gels (1 TBE) and stained with ethidium bromide.
Quantitative real-time PCR
Purified RNA was reverse transcribed with the TaqMan Reverse Trans-
cription Reagents kit (Applied Biosystems, Weiterstadt, Germany) with
random hexamers as primers. TaqMan experiments were carried out
on an ABI PRISM 7000 Sequence Detection System (Applied
Biosystems) using Assay-on Demand gene expression products for
CYP26AI (Hs00175627) according to the manufacturer’s recommen-
dations. An Assay-on-Demand product for 18S rRNA (Hs99999901)
was used as an internal reference to normalize the target transcripts.
CYP26AI and 18S rRNA sequences were amplified independently in
separate reaction wells in triplicate. The real-time PCR efficiencies
were determined for each primer/probe set from standard curves
generated from serial dilutions of a cDNA sample of unstimulated
dermal fibroblasts and keratinocytes. The relative differences between
the CYP26AI expression of unstimulated and stimulated cells were
calculated using the mathematical model developed by Pfaffl (2001)
including the PCR efficiencies.
Development and evaluation of the peptide antibody against
the N-terminus of CYP26AI
Peptide synthesis and generation and purification of the anti-peptide
antibody against the N-terminus of CYP26AI were carried out in
cooperation with Alpha Diagnostic International Inc. (San Antonio,
TX). An affinity-purified antiserum from rabbit and the peptide (CLS
NLH DSS HKQ RKK) was supplied by the company. Two
approaches for verifying the specificity of the peptide sequence for
CYP26AI in silico were used. Firstly, the NCBI protein database was
searched using the above peptide sequence as query for similar
sequences using the protein–protein Basic Local Alignment Search
Tool (blastp) with standard conditions (expect: 10; wordsize:3;
Matrix: BLOSUM62; no filters) (Altschul et al., 1990). This yielded
only CYP26AI as significant result. Secondly, we performed a
multiple sequence alignment of human CYP26AI with known related
human sequences CYP26B1 (White et al., 2000) and CYP26C1
(Taimi et al., 2004) using the CLUSTAL W algorithm (Higgins et al.,
1994) with results shown in Table 1. Aside from the complete
identity with CYP26AI, there is no significant similarity with other
human CYP26 proteins.
Furthermore, the anti-peptide antibody specificity was assessed
by competing with an excess of peptide. To neutralize the antibody,
an adequate volume of antibody was incubated with two different
amounts of peptide at 371C for 2 and 16 hours at 41C. The control
reaction did not contain any peptide. After incubation, the probes
were centrifuged for 15 minutes at 41C and 13,000 r.p.m. to pellet
any immune complexes. The supernatants were removed carefully
and used instead of the first antibody in the Western blotting (Figure
S1), immunohistochemistry (Figure S2), and immunofluorescence
(Figure S3) procedure. The disappearance of the immunoreactive
band and tissue staining pattern after competitive incubation with
the peptide indicates the specificity of the CYP26AI antibody
(Figures S1–3).
Cell lysates and Western blotting
NHEK and human dermal fibroblasts were exposed to 106 M
all-trans RA for the indicated periods of time after which, the cells
2478 Journal of Investigative Dermatology (2006), Volume 126
R Heise et al.
Role of CYP26AI in Retinoid Homeostasis of the Skin
were lysed in Triton lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM
NaCl 1% Triton X-100, 1 mM EDTA, 10 mM NaF, 1 mM Na3VO4,
1 mM phenylmethylsulfonyl fluoride, 5 mg/ml aprotinin, and 5 mg/ml
leupeptin), scraped off the dish, and left on ice for 30 minutes.
Lysates were centrifuged with 14,000 g for 10 minutes at 41C and
equal amounts of protein were boiled for 5 minutes in Laemmli
buffer at 951C. Proteins were separated by SDS-PAGE in 12% gels,
followed by electroblotting onto a polyvinylidene difluoride
membrane (Bio-Rad, Mu¨nchen, Germany). Immunodetection was
performed with the enhanced chemiluminescence kit (Amersham
Biosciences, Freiburg, Germany) using a primary generated peptide
antibody against the N-terminus of CYP26AI (Alpha Diagnostic
International Inc., San Antonio) and a secondary goat anti-rabbit IgG
antibody conjugated to horseradish peroxidase (Dako, Glostrup,
Germany). Blots were stripped in 2% SDS and 100 mM
b-mercaptoethanol in 62.5 mM Tris-HCl (pH 6.7) for 20 minutes at
751C and reprobed with a primary monoclonal anti-human b-actin
antibody (Sigma-Aldrich, Mu¨nchen, Germany) and a secondary
rabbit anti-mouse IgG antibody conjugated to horseradish perox-
idase (Dako, Glostrup, Germany). Relative immunoreactivity was
defined by performing a densitometric analysis using an LTF Image
Analysis System (LTF, Wasserburg, Germany).
Immunohistochemistry
Paraffin-embedded skin specimen from normal human skin was cut
into 4 mm sections, mounted on superfrost slides (Menzel, Braunsch-
weig, Germany), deparaffinized, and rehydrated. To unmask
antigens, the specimens were pretreated with citrate buffer pH 6.0
(DCS, Hamburg, Germany) according to the manufacturer’s instruc-
tions, rinsed in distilled water, and placed in washing buffer (DCS).
Specimens were incubated for 30 minutes with primary antibody,
either the peptide antibody against the N-terminus of CYP26AI
(Alpha Diagnostic International Inc., San Antonio) or the isotypic
control, and rinsed in washing buffer (DCS) for 10 minutes (Baron
et al., 2001). Binding of the antibodies was visualized by the DCS
Detection Line HRP/AEC (DCS) as specified by the manufacturer.
Finally, specimens were counterstained with hematoxylin and
mounted with coverslips. Examination and photodocumentation
were performed using an inverse photomicroscope (LEICA DMIL,
Leitz).
Immunofluorescence
For immunofluorescence examination of monolayers, cells were
seeded into chamber slides (four-well Lab-Tek II, NUNC). NHEKs
were fixed in ice-cold methanol for 10 minutes and rinsed in TBS.
Besides samples of normal human skin, skin taken from patients with
psoriasis and skin equivalents, both untreated and treated with the
aryl hydrocarbon receptor (AHR) ligand liquor carbonis detergens at
0.26% for 24 hours, were embedded in Tissue Tek optimal cutting
temperature compound (OCT; Sakura, Zoeterwoude, NL). Cryo-
sections of 4mm thickness were fixed in acetone for 10 minutes and
air dried at 41C. Both the chamber slides and the slides bearing the
fixed skin sections were blocked in TBS/1% BSA (DAKO, Carpinter-
ia, CA, Serva) for 30 minutes, followed by incubation at room
temperature for 1 hour with the the primary peptide antibody against
the N-terminus of CYP26AI (Alpha Diagnostic International Inc., San
Antonio) diluted 1:100 in Antibody Diluent (Dako, Glostrup,
Denmark). Subsequently, slides were washed three times for
10 minutes with TBS followed by an incubation for 30 minutes with
a secondary FITC-conjugated goat anti-rabbit antibody (Alexa Fluor
488, Molecular Probes, Invitrogen GmbH, Karlsruhe, Germany),
washed two times for 10 minutes with TBS (Serva, Heidelberg),
mounted in Fluoroprep (BioMerieux, Marcy iEtoile, France), and
coverslipped.
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